These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31365162)

  • 1. Effectiveness and safety of two different antithymocyte globulins used in induction therapy in kidney transplant recipients: A single-center experience.
    Styrc B; Sobolewski M; Chudek J; Kolonko A; Więcek A
    Clin Transplant; 2019 Oct; 33(10):e13680. PubMed ID: 31365162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with thymoglobulin and antithymocyte globulin-Fresenius as induction therapy in renal transplant patients: a retrospective study.
    Cicora F; Mos F; Paz M; Roberti J
    Exp Clin Transplant; 2013 Oct; 11(5):418-22. PubMed ID: 23909577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety between rabbit anti-thymocyte globulin and anti-T lymphocyte globulin in kidney transplantation from donation after cardiac death: a retrospective cohort study.
    Chen GD; Lai XQ; Ko DS; Qiu J; Wang CX; Han M; Li J; Huang G; He XS; Chen LZ
    Nephrology (Carlton); 2015 Aug; 20(8):539-43. PubMed ID: 25808082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prednisone-free maintenance immunosuppression in obese kidney transplant recipients.
    Matas AJ; Vock DM
    Clin Transplant; 2019 Oct; 33(10):e13668. PubMed ID: 31310030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-T-Lymphocyte Immunoglobulin (Grafalon) as an Induction Agent for Renal Transplantation: A Real-World, Retrospective, Single-Center Experience.
    Gupta A; Bhalla AK; Malik M; Gupta A; Bhargava V; Tiwari V; Gaur L; Gupta P; Jain M; Rana DS
    Exp Clin Transplant; 2022 May; 20(5):480-486. PubMed ID: 35620891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Thymoglobulin and Grafalon as Induction Agents in Renal Transplantation: A Prospective Study.
    Thukral S; Rokde R; Ray DS
    Transplant Proc; 2022 Oct; 54(8):2133-2139. PubMed ID: 36116944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between thymoglobulin and ATGAM as an induction agent in adult kidney transplantation: a single-center experience.
    Kim JM; Jang HR; Ko JS; Kwon CH; Kwak MS; Hur WS; Kim SJ; Kim GS; Joh JW; Lee SK; Oh HY
    Transplant Proc; 2012 Jan; 44(1):171-4. PubMed ID: 22310607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.
    Kucirka LM; Durand CM; Bae S; Avery RK; Locke JE; Orandi BJ; McAdams-DeMarco M; Grams ME; Segev DL
    Am J Transplant; 2016 Aug; 16(8):2368-76. PubMed ID: 27111897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
    Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
    Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The appropriate dose of thymoglobulin induction therapy in kidney transplantation.
    Nafar M; Dalili N; Poor-Reza-Gholi F; Ahmadpoor P; Samadian F; Samavat S
    Clin Transplant; 2017 Jun; 31(6):. PubMed ID: 28376289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
    Peng W; Liu G; Xie W; Huang H; Wu J; Shou Z; Chen J
    Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
    Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
    Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study.
    Hellemans R; Hazzan M; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Noël C; Abramowicz D
    Am J Transplant; 2015 Jul; 15(7):1923-32. PubMed ID: 25707875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
    Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M
    Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of Two Types of Rabbit Antithymocyte Globulin Induction Therapy in Immunological High-Risk Kidney Recipients: A Prospective Randomized Control Study.
    Burkhalter F; Schaub S; Bucher C; Gürke L; Bachmann A; Hopfer H; Dickenmann M; Steiger J; Binet I
    PLoS One; 2016; 11(11):e0165233. PubMed ID: 27855166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.